Cerebral Ventricle Cancer Overview

Save information for later
Sign Up

Learn About Cerebral Ventricle Cancer

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Cerebral Ventricle Cancer Local Doctors?
Elite in Cerebral Ventricle Cancer
Elite in Cerebral Ventricle Cancer
Toronto, ON, CA 

David Malkin practices in Toronto, Canada. Mr. Malkin is rated as an Elite expert by MediFind in the treatment of Cerebral Ventricle Cancer. His top areas of expertise are Li-Fraumeni Syndrome, Cerebral Ventricle Cancer, Choroid Plexus Carcinoma, and Rhabdomyosarcoma.

Elite in Cerebral Ventricle Cancer
Elite in Cerebral Ventricle Cancer
Toronto, ON, CA 

Uri Tabori practices in Toronto, Canada. Mr. Tabori is rated as an Elite expert by MediFind in the treatment of Cerebral Ventricle Cancer. His top areas of expertise are Glioma, Choroid Plexus Carcinoma, Cerebral Ventricle Cancer, and Gliomatosis Cerebri.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Cerebral Ventricle Cancer
Elite in Cerebral Ventricle Cancer
Marker Allee 76-78, 
Hamm, RP, DE 

Christian Thomas practices in Hamm, Germany. Mr. Thomas is rated as an Elite expert by MediFind in the treatment of Cerebral Ventricle Cancer. His top areas of expertise are Cerebral Ventricle Cancer, Choroid Plexus Carcinoma, Choroid Plexus Papilloma, Rhabdoid Tumor, and Thrombectomy.

What are the latest Cerebral Ventricle Cancer Clinical Trials?
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Summary: The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) ne...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification

Summary: Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO cl...